Get the Stockscreener App
9.21
8.35%
0.71
Kala Bio Inc stock is traded at $9.21, with a volume of 150.66K.
It is up +8.35% in the last 24 hours and up +67.45% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$8.50
Open:
$8.59
24h Volume:
150.66K
Relative Volume:
1.37
Market Cap:
$64.66M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.7386
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+10.70%
1M Performance:
+67.45%
6M Performance:
+38.70%
1Y Performance:
+53.50%
1-Day Range:
$8.5291
$9.225
1-Week Range:
$7.71
$9.225
52-Week Range:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
9.21 | 60.24M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Tools to monitor KALA BIO Inc. recovery probabilityWeekly Market Outlook & Accurate Intraday Trade Tips - Newser
Relative strength of KALA BIO Inc. in sector analysisDip Buying & Intraday High Probability Setup Alerts - Newser
KALA BIO Inc. Recovery Gathers Momentum on Chart SignalsJuly 2025 Institutional & Expert Curated Trade Setups - thegnnews.com
What’s next for KALA BIO Inc. stock priceMarket Movement Recap & Technical Confirmation Alerts - Newser
Multi asset correlation models including KALA BIO Inc.July 2025 Technicals & Safe Capital Growth Plans - Newser
KALA BIO Inc.’s volatility index tracking explainedEarnings Recap Summary & Fast Entry Momentum Trade Alerts - Newser
Price momentum metrics for KALA BIO Inc. explainedWeekly Market Summary & Long-Term Growth Stock Strategies - Newser
Statistical indicators supporting KALA BIO Inc.’s strengthJuly 2025 Breakouts & Daily Technical Stock Forecast Reports - Newser
Signal strength of KALA BIO Inc. stock in tech scannersCEO Change & Weekly Watchlist for Hot Stocks - Newser
Can you recover from losses in KALA BIO Inc.2025 Geopolitical Influence & Community Consensus Trade Signals - Newser
Using Python tools to backtest KALA BIO Inc. strategiesQuarterly Performance Summary & Low Risk High Win Rate Picks - Newser
Will KALA BIO Inc. continue its uptrendWeekly Profit Summary & Fast Exit and Entry Strategy Plans - Newser
What makes KALA BIO Inc. stock price move sharplyPortfolio Risk Summary & Real-Time Volume Trigger Notifications - Newser
Published on: 2025-08-19 05:14:53 - newsimpact.co.kr
Can KALA BIO Inc. recover in the next quarterBond Market & Accurate Buy Signal Alerts - Newser
KALA BIO Inc. Building a Base Near Support2025 Earnings Surprises & AI Powered Buy/Sell Recommendations - classian.co.kr
Is KALA BIO Inc. showing insider buying2025 Year in Review & Technical Entry and Exit Tips - newsyoung.net
What candlestick patterns are forming on KALA BIO Inc.Market Movement Recap & Technical Confirmation Alerts - Newser
Trend analysis for KALA BIO Inc. this weekPortfolio Return Summary & High Conviction Investment Ideas - Newser
Comparing KALA BIO Inc. in custom built stock radarsWeekly Profit Analysis & Reliable Entry Point Trade Alerts - Newser
Equities Analysts Offer Predictions for KALA BIO Q3 Earnings - Defense World
KALA BIO Inc. Company’s Quarterly Earnings Growth: What the Numbers SayJuly 2025 Spike Watch & Capital Protection Trading Alerts - Newser
KALA BIO Inc. Reversal Rally May Surprise BearsRate Hike & Weekly High Return Forecasts - beatles.ru
Technical analysis overview for KALA BIO Inc. stockRate Hike & Fast Entry Momentum Trade Alerts - Newser
KALA BIO Inc. Stages Intraday Comeback — Trend ChangeWeekly Trend Report & Fast Moving Stock Watchlists - sundaytimes.kr
How KALA BIO Inc. stock performs during market volatility2025 Trading Volume Trends & Daily Growth Stock Investment Tips - Newser
Is KALA BIO Inc. a Top Dividend Stock to Watch in 2025Earnings Risk Summary & Weekly Watchlist for Consistent Profits - Newser
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 24 '25 |
Sale |
4.01 |
3,631 |
14,560 |
62,100 |
| Bazemore Todd | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
4,058 |
16,273 |
83,699 |
| Brazzell Romulus K | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
5,251 |
21,057 |
82,698 |
| Iwicki Mark T | Director |
Jun 24 '25 |
Sale |
4.01 |
13,227 |
53,040 |
258,433 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):